Key Insights

Highlights

Treatment Research

1 treatments under study, led by Il4r

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05428410Unknown

Study on Biomarkers to Predict the Efficacy of IL-4R Monoclonal Antibody for Chronic Rhino-sinusitis With Polyps

Showing all 1 trials

Research Network

Common Treatments

  • Il4r1

Active Sponsors

  • Beijing Tongren Hospital1

Top Investigators

Related Conditions

  • Chronic Rhinosinusitis1
  • Monoclonal Antibody1
  • Biomarker1

Activity Timeline